Phase IIb trial of ATL 1102 in patients with multiple sclerosis

Trial Profile

Phase IIb trial of ATL 1102 in patients with multiple sclerosis

Planning
Phase of Trial: Phase II

Latest Information Update: 24 Oct 2014

At a glance

  • Drugs ATL 1102 (Primary)
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Sponsors Antisense Therapeutics
  • Most Recent Events

    • 24 Oct 2014 According to Antisense Therapeutics media release, US FDA has responded affirmatively to the Company plan to submit a U.S. Investigational New Drug (IND) application for initiation of this phase II trial.
    • 19 Aug 2014 Antisense Therapeutics has submitted a formal request for the US FDA's assessment of ANP's plans for a Phase IIb trial of ATL1102 in MS patients.
    • 19 Mar 2013 Planned initiation date changed to 1 Jan 2014, based on information in an Antisense Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top